← 產業報告目錄
Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Ergot Alkaloids, Non-Ergot Dopamine Agonists), By Application (Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia, Others), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies), By Region, And By Segment Forecasts, 2025-2034.
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-03頁數 180報告編號 INSIGHTACE-9b40e35499
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Dopamine Agonist Market stood at USD 1.4 billion in 2024, and is expected to reach USD 2.9 billion by 2034, recording a CAGR of 7.4% from 2025 through 2034.
The Dopamine Agonist sector involves a class of drugs that imitate the effects of dopamine by activating dopamine receptors in the brain. This domain has witnessed pronounced transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Dopamine Agonist Market Snapshot
Chapter 4. Global Dopamine Agonist Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Dopamine Agonist Market Industry Trends
4.10. Global Dopamine Agonist Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Dopamine Agonist Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug:
5.2.1. Ergot Alkaloids
5.2.2. Non-Ergot Dopamine Agonists
Chapter 6. Dopamine Agonist Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Parkinson's Disease
6.2.2. Restless Legs Syndrome (RLS)
6.2.3. Hyperprolactinemia
6.2.4. Others
Chapter 7. Dopamine Agonist Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
7.2.1. Oral
7.2.2. Injectable
7.2.3. Others
Chapter 8. Dopamine Agonist Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Other Pharmacies
Chapter 9. Dopamine Agonist Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Dopamine Agonist Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.2.3. North America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.4. North America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.2.5. North America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
9.3. Europe
9.3.1. Europe Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.3.3. Europe Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.4. Europe Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3.5. Europe Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.4.3. Asia Pacific Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.4. Asia Pacific Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4.5. Asia Pacific Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
9.5. Latin America
9.5.1. Latin America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.5.3. Latin America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.4. Latin America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5.5. Latin America Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.6.3. Middle East & Africa Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.6.4. Middle East & Africa Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.6.5. Middle East & Africa Dopamine Agonist Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Teva Pharmaceutical Industries Ltd
10.2.1.1. Business Overview
10.2.1.2. Key Drug/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. GSK plc.
10.2.3. Supernus Pharmaceuticals, Inc.
10.2.4. H. Lundbeck A/S
10.2.5. Amneal Pharmaceuticals LLC
10.2.6. UCB Pharma
10.2.7. Novartis AG
10.2.8. VeroScience LLC.
10.2.9. Pfizer Inc.
10.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們